Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC By Ogkologos - August 27, 2025 570 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PEACE-3 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR ESMO Calls on the European Commission to Fund Cancer Research and... September 23, 2026 TAT 2021 Honorary Award: A Recognition in Cancer Drug Development to... February 16, 2021 Amid Coronavirus Outbreak and Panic Buying, Stores Introduce Special Shopping Times... March 18, 2020 Plans for NCI’s Fiscal Year 2019 Budget December 18, 2018 Load more HOT NEWS What Are Clinical Practice Guidelines and How Do They Impact Care... EMA Recommends Granting a Conditional Marketing Authorisation for Zanidatamab Aided by Community Health Workers, People with Advanced Cancer Need Fewer... Can a Biopsy Make My Cancer Spread?
